Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.

Pustular psoriasis is an unusual form of psoriasis that frequently presents clinical challenges for dermatologists. The condition presents with pustules on an erythematous background and has two distinct subtypes: localized disease on the palms and soles, called palmoplantar pustulosis (PPP), and generalized pustular psoriasis (GPP). The involvement of the fingers, toes, and nails is defined as a separate localized variant, acrodermatitis continua of Hallopeau, and is now thought to be a subset of PPP. The rarity of pustular psoriasis frequently makes the correct diagnosis problematic. In addition, treatment is limited by a relative lack of evidence-based therapeutic options. Current management is often based on existing therapies for standard plaque psoriasis. However, there remains a need for treatments with high, sustained efficacy and a rapid onset of action in pustular psoriasis. Recent advances in understanding of the pathogenesis of pustular psoriasis have provided insights into potential therapies. Treatment of pustular psoriasis is generally determined by the extent and severity of disease, and recent years have seen an increasing use of newer agents, including biologic therapies. Current classes of biologic therapies with US Food and Drug Administration and European Medicines Agency approval for treatment of moderate-to-severe plaque psoriasis in the USA (and elsewhere) include tumor necrosis factor alpha inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab), interleukin (IL)-17 inhibitors (brodalumab, ixekizumab, secukinumab), an IL-12/23 inhibitor (ustekinumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. The emerging drugs for pustular psoriasis offer the possibility of rapid and effective treatment with lower toxicities than existing therapies. Further research into agents acting on the IL-36 pathway and other targeted therapies has the potential to transform the future treatment of patients with pustular psoriasis. This article reviews the clinical features of PPP and GPP, and current understanding of the genetics and immunopathology of these conditions; it also provides an update on emerging treatments.

Key Summary Points

Digital Features

This article is published with digital features, including an infographic, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.16592891.

Introduction

Pustular psoriasis is a form of psoriasis characterized by neutrophil-containing pustules on an erythematous background [1]. It is distinct from the more common plaque psoriasis—not only clinically but also histologically and genetically [2]. Pustular psoriasis is generally considered to be idiopathic, although genetic factors do play a role in disease susceptibility. The condition has two distinct subtypes: localized disease occurring on the palms and soles, known as palmoplantar pustulosis (PPP; also called palmoplantar pustular psoriasis), and generalized pustular psoriasis (GPP). The involvement of the fingers, toes, and nails is defined as a separate localized variant, acrodermatitis continua of Hallopeau, which is now thought to be a subset of PPP.

Pustular psoriasis generally follows a relapsing and remitting course, requiring long-term disease management. Precipitating and exacerbating factors include smoking, infections, withdrawal from medications (e.g., systemic corticosteroids, methotrexate, and cyclosporine), and pregnancy. In addition, the use of tumor necrosis factor alpha (TNFα) inhibitors may occasionally cause paradoxical triggering of immune-mediated skin diseases, including pustular psoriasis [3-5]. At present, there is limited evidence on which to base treatment recommendations for pustular psoriasis, partly due to the less common nature of the condition, and current therapies are based on existing treatments for plaque psoriasis [6, 7]. Nonetheless, recent advances in understanding of the pathogenesis of pustular psoriasis have provided insights into possible targeted therapies, including biologic therapies. This article reviews the clinical features of PPP and GPP, in addition to recent developments in our understanding of the genetics and immunology of the conditions. An update on potential new treatments is also included.

Methods

The Medline database was searched via PubMed to retrieve relevant articles on generalized pustular psoriasis, palmoplantar pustulosis, and pustular psoriasis published between 2015 and 2020 (limits: humans, English language). Other relevant literature was obtained on the basis of personal knowledge and experience of the authors. Manual assessment of retrieved references was used as the basis for a narrative overview of the literature.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Results

Pustular Psoriasis: PPP

PPP is the most common variant of pustular psoriasis; it has a reported prevalence of 0.05–0.12% and is significantly more prevalent in Japan than in Western countries [8, 9]. PPP is a chronic, refractory disease that is associated with major impairment of health-related quality of life, resulting from pain and pruritus [10]. The condition presents with pustules on the palms and soles and is frequently accompanied by erythema, pain, and scaling. The clinical diagnosis of PPP is made in the presence of primary, chronic pustules on the palms, soles, or both (Fig. 1a) [11]. Patients may complain of severe burning pain. When the sterile pustules resolve, there are often brown macules and scaling. The nails may also be affected. The diagnosis of PPP is generally straightforward, although differential diagnoses should be excluded (Fig. 1b).

Fig. 1

Clinical features of PPP (a) and differential diagnosis (b). PPP palmoplantar pustulosis

Smoking and female sex are common risk factors for the development of PPP [12]. Other factors that can precipitate or exacerbate PPP include infections (e.g., tonsillitis and dental infections) and psychological stress [13-15]. PPP can also be precipitated or exacerbated by certain drugs, including TNF inhibitors (infliximab, etanercept, and adalimumab) used for other conditions, such as rheumatoid arthritis or Crohn’s disease [16], and interleukin (IL)-17 inhibitors, used for the treatment of psoriasis [4, 5]. The pathophysiology of this paradoxical drug effect has not been clearly described, but it appears to result from an increased expression of type 1 interferon (IFN) alpha (IFNα), IFNγ, and proinflammatory cytokines (IL-36, IL-19, and IL-20) [17]. Recent research suggests that IFNα is produced by CD3/CD4/T-bet-positive type 1 helper T cells [18]. This paradoxical response, which develops in a small minority of patients who receive TNF inhibitor therapy, is likely due to an undetermined genetic predisposition [16].

Genetics and Immunopathogenesis of PPP

At present, the mechanism underlying the development of PPP is not well understood, and the known genes associated with pustular psoriasis account for only a minority of PPP cases [12]. However, mutations of the caspase recruitment domain-containing protein 14 (CARD14) gene have been associated with PPP in European patients [19], in addition to AP1S3 gene mutations [12]. Overexpression of sweat antimicrobial peptide is thought to underlie the development of PPP [20], and the inflammatory process of PPP likely originates in the acrosyringia, resulting in their destruction [13]. The IL36γ gene, which encodes the inflammatory cytokine IL-36γ, is upregulated in patients with PPP, indicating that dysregulation of the IL-36 pathway is involved in the development of skin lesions in these patients [21]. Stimulation of the IL-36 receptor results in the activation of nuclear factor (NF)-κB and the secretion of IL-8 (a chemokine for neutrophils), pro-inflammatory cytokines TNFα, IL-1 and IL-23, and an increase in Th-17 activity [20]. In addition to overactivity of the IL-36 pathway, activation of the IL-17 pathway is seen in patients with PPP [22]. IL-17 is produced by T cells and other cell types, including neutrophils and mast cells, contributing to the inflammatory processes underlying PPP, as well as plaque psoriasis [22].

Pustular Psoriasis: GPP

GPP is a rare skin disease that has an estimated worldwide incidence of 2–7 per million [23, 24]. The condition is characterized by widespread eruption of neutrophilic, sterile pustules, which characteristically have surrounding erythema. According to the European Rare and Severe Psoriasis Expert Network definition, GPP can occur with or without systemic inflammation [11]. In contrast, Japanese guidelines for the management of GPP state that GPP is considered to be a systemic inflammatory condition, with patients having abnormal clinical findings associated with inflammation, such as fever and raised levels of C-reactive protein [25]. The clinical course of GPP varies between individual patients, and can follow a relapsing or persistent course. The severity of symptoms can vary with each disease flare and within each individual patient (Fig. 2a) [2]. Patients with GPP require careful management, since severe cases can result in life-threatening complications (e.g., sepsis, cardiorespiratory failure) [25, 26]. Japanese guidelines for the management and treatment of GPP define four main features of the disease: (1) systemic symptoms (e.g., high fever, fatigue); (2) systemic or widespread pustules; (3) subcorneal pustules with neutrophils histopathologically characterized by Kogoj’s spongiform pustules; and (4) the frequent recurrence of these features [25, 27]. Differential diagnoses of GPP should be excluded when relevant, in particular drug eruptions such as acute generalized exanthematous pustulosis (associated with drugs such as amoxicillin or nonsteroidal anti-inflammatory drugs) [28] (Fig. 2b).

Fig. 2

Clinical features of GPP (a) and differential diagnosis (b). GPP generalized pustular psoriasis

Several factors can precipitate or exacerbate acute GPP. Withdrawal of systemic corticosteroids is a known trigger for GPP flares [29]. Other triggers include pregnancy (GPP in pregnancy was previously also known as impetigo herpetiformis) [30], stress, and TNFα inhibitors [1, 2]. In addition, infectious respiratory viruses have been identified as trigger factors among a small cohort of patients with various psoriasis subtypes, including GPP [31]. It is possible that the viral infection and associated stimulation of the innate immune system produce a dysregulated immune response that leads to the onset of GPP.

Genetics and Immunopathogenesis of GPP

The proposed immunopathogenetic mechanisms underlying the development of GPP are complex and have been reviewed by Bachelez et al. [2], Furue et al. [32], and Johnston et al. [33]. The histopathology of GPP is characterized by extensive epidermal infiltration by neutrophils and mononuclear cells, leading to the development of clinically visible, sterile pustules [1, 11]. Overexpression of IL-36 or a loss-of-function mutation of its antagonist, IL-36RA, is thought to play a central role in the pathogenesis of pustular psoriasis [34, 35]. Mutations of the IL36RN gene encoding the IL-36RA are the most frequent genetic abnormality associated with GPP, especially in European and East Asian populations [12], with a reported frequency of IL36RN gene mutation of between 23% and 61% [12, 34, 36–40]. The greater frequency of IL-36 mutations in GPP versus PPP is an important indicator that the two conditions are genetically and immunopathologically distinct.

Mutation of the IL36RN gene results in an unstable IL-36RA protein with a reduced affinity for its receptor [34]. The IL-36RA molecule inhibits the effects of several IL-36-associated cytokines, including members of the IL-1 cytokine family (IL-36α, IL-36β, and IL-36γ), which are abundantly expressed in the skin. Binding of IL-36R by an agonist cytokine in the IL-1 family results in uncontrolled activation of the transcription factor, NF-κB. This leads to activation of proinflammatory pathways via massive release of inflammatory mediators, such as CXCL8, TNFα, IL-1, and IL-23 from keratinocytes, macrophages, and dendritic cells [2, 33]. In the absence of a functional IL-36RA, IL-36 is uninhibited in its ability to enhance the levels of proinflammatory mediators [1]. The IL-36 receptor is found on several skin cell types and, when activated, leads to inflammation of the skin and symptoms of GPP.

Mutations or variants of CARD14, a key regulator of skin immune homeostasis, are also associated with GPP [41, 42]. Mutations of the AP1S3 gene have also been found in subtypes of pustular psoriasis, mainly in GPP and localized PPP (acrodermatitis continua of Hallopeau). The resulting structural and functional changes in the adaptor protein 1 family lead to deregulation of innate immune responses in the skin [43, 44].

Treatment Options

In general, treatment for pustular psoriasis is determined by the extent and severity of the disease. Although pustular psoriasis is distinct from plaque psoriasis, most therapies for PPP and GPP have been based on traditional treatment approaches for plaque psoriasis [45, 46]. From the 1980s to the early 2000s, there has been a trend toward increasing use of high potency topical corticosteroids for the management of plaque psoriasis [47]. However, treatment may also include phototherapy, systemic therapies (e.g., cyclosporine, methotrexate, acitretin, apremilast), and systemic immunomodulatory agents (biologic therapies) [1]. Clinical experience suggests that biologic therapies with the greatest efficacy for plaque psoriasis are also more likely to be effective in pustular psoriasis, although clinical trial data in pustular psoriasis are limited [48]. Current classes of biologic therapies with approval from the US Food and Drug Administration and the European Medicines Agency for treatment of moderate-to-severe plaque psoriasis in the USA (as well as other countries) include four TNFα inhibitors (adalimumab, certolizumab pegol, etanercept, and infliximab), three IL-17 inhibitors (brodalumab, ixekizumab, and secukinumab), an IL-12/23 inhibitor (ustekinumab), and three IL-23 inhibitors (guselkumab, risankizumab, and tildrakizumab) [6, 48–50].

Treatments for PPP

At present, there is insufficient evidence to determine which therapies are most effective for chronic PPP [15, 48]. Current treatment options include superpotent corticosteroids (with or without occlusion), phototherapy, and systemic therapies (Fig. 3) [10, 51]. However, the use of systemic immunosuppressant agents can be associated with a slow onset of action and poor tolerability [1, 46].

Fig. 3

Treatment algorithm for pustular psoriasis. GPP generalized pustular psoriasis, IL interleukin, PUVA psoralen + ultraviolet light A, TNF tumor necrosis factor, UVB ultraviolet B

Guselkumab, an IL-23 monoclonal antibody, is the first biologic therapy to have demonstrated moderate efficacy and a good safety profile in Japanese patients with PPP [10, 52, 53]. Ustekinumab, an inhibitor of IL-12 and IL-23, has been used in the treatment of PPP, but evidence for its efficacy is conflicting [10, 15]. The IL-17 inhibitor secukinumab has also been evaluated for moderate-to-severe PPP, but did not demonstrate superiority versus placebo in achievement of the primary endpoint (75% improvement from baseline in Palmoplantar Pustulosis Psoriasis Area and Severity Index [PPPASI]) [54]. Brodalumab, another IL-17 inhibitor, has been evaluated in PPP and has demonstrated either no improvement or moderate improvement in a recent case series of treated patients [55]. A small (N = 15), randomized, placebo-controlled, prospective study of a TNFα inhibitor, etanercept, has shown mixed results, with some patients experiencing improvements and others showing worsening PPP [56]. Apremilast, an oral phosphodiesterase 4 inhibitor, also has moderate evidence of clinical efficacy in PPP [10].

Recent trials in PPP have focused on blockade of the IL-1 or IL-36 pathways, which have a central role in innate immunity [10, 51]. Anakinra, a recombinant IL-1 receptor antagonist, is undergoing evaluation in patients with PPP [57]. The novel IL-36 receptor inhibitor spesolimab has been shown to be effective in a phase 1 proof-of-concept study of seven patients with GPP; it is also being evaluated in patients with PPP [58-60]. The efficacy of spesolimab in patients with GPP was demonstrated regardless of the presence of IL36RN mutation, a finding that may be of importance for patients with PPP, since this mutation occurs in only a minority of cases. The efficacy and safety of spesolimab was assessed in a placebo-controlled pilot study of 59 patients with PPP [61]. Although the primary endpoint was not met (proportion of patients achieving a 50% reduction in PPPASI score at week 16 for spesolimab vs. placebo), a post hoc subanalysis of patients with baseline PPPASI above median showed rapid improvement with spesolimab versus placebo in this subgroup; a further trial is currently under way. Another IL-36 receptor inhibitor, imsidolimab, is also under evaluation in patients with PPP [62]. Further targeted therapies are currently being investigated for use in PPP, with targets including CXCR2 (an IL-8 receptor type B agent) and granulocyte colony-stimulating factor receptors, IL-12, and TNFα [10].

Treatments for GPP

The clinical trial evidence for GPP is more limited than for PPP because of the rarity of GPP. The spontaneously remitting pattern of acute GPP flares also makes clinical evaluation of therapies difficult [2]. As a result, there is a lack of evidence-based treatment guidelines [1], and clinicians must rely on evidence from open-label studies and case reports for guidance on efficacy in GPP [63-65]. Treatment options for patients with GPP are limited and based on existing therapies for plaque psoriasis [25]. Most therapies show weak evidence of efficacy in GPP, and some agents are not well tolerated [25]. Most patients with mild-to-moderate symptoms can experience symptom reduction with topical medications or phototherapy, although these options are unlikely to be effective for patients with more severe disease. Biologic therapies, as monotherapy or combined with other topical or systemic medications, offer additional treatment options (Fig. 3). While IL-36 inhibitors, such as spesolimab, have the potential to increase the treatment options for patients with GPP, these agents are not currently approved in the USA and are, therefore, not included in the current treatment algorithm. For the management of GPP in pregnancy, special consideration is required. Initial treatment for pregnant women involves cyclosporine 4–5 mg/kg of ideal body weight divided into two doses per day [66, 67]. Second-line options include corticosteroids (such as prednisolone or prednisone, with monitoring for potential rebound exacerbation after treatment cessation) or biologic therapies (faster acting IL-17 or IL-23 inhibitors, or certolizumab, which does not cross the placenta) (Fig. 3). The associated placental insufficiency, which is potentially life-threatening to the unborn child, requires an efficacious medication that has a rapid onset of action [25].

There remains a need for an effective treatment with a rapid onset of action, and for robust clinical trial data to guide treatment decisions. Newer treatments for GPP are emerging, including IL-17 inhibitors, which have been approved for the treatment of GPP in Japan (IL-17A monoclonal antibodies: brodalumab, ixekizumab, and secukinumab) [48, 68]. Other approved agents for GPP in Japan are IL-23 agents, guselkumab and risankizumab, and TNFα agents, infliximab and adalimumab [48, 68]. Anakinra, a recombinant IL-1 receptor antagonist, has also been reported to reduce symptoms in two case series of patients with GPP and IL36RN mutations [69, 70].

High levels of TNFα, a cytokine that activates proinflammatory nuclear transcription factors and keratinocyte proliferation, are a key pathogenic feature of the skin inflammation that characterizes GPP [71]. First-generation biologic therapies target TNFα, with a potentially lower risk of end-organ damage compared with traditional treatments. Etanercept, a fusion protein containing human TNFα receptor, has been shown to be moderately effective in reducing the symptoms of GPP [72], including pediatric GPP [73]. More recently, specific inhibitors of the IL-36 pathway are emerging for the management of both GPP and PPP. Of these, the IL-36 receptor inhibitor spesolimab is at the most advanced stage of development, with confirmatory trials currently under way in GPP. In a phase 1 proof-of-concept study (NCT02978690), a single infusion of spesolimab to seven patients with moderate-to-severe GPP flares was associated with rapid and sustained improvements in clinical symptoms [60]. A Generalized Pustular Psoriasis Physician Global Assessment score of 0 or 1 was achieved within 1 week and sustained to week 20, irrespective of the presence of IL36RN mutation. Pustules were completely clear in three patients within 48 h after treatment, in five patients by week 1, and in six patients by week 2 [60]. The findings of this proof-of-concept study suggest that IL-36 receptor inhibition with a single dose of spesolimab could significantly reduce the severity of GPP over a 20-week period. Since GPP is a systemic disease, it is of interest that spesolimab was also associated with a rapid and sustained reduction in inflammation, as indicated by reductions in C-reactive protein and neutrophil levels to week 4 [60]. Another IL-36 receptor inhibitor, imsidolimab, is also being evaluated in GPP and PPP, and phase 2 trials are ongoing [74]. Further research into agents acting on the IL-36 pathway and other targeted therapies has the potential to transform the treatment of patients with pustular psoriasis for whom few effective treatment options are currently available.

Discussion

Clinical Management of Patients with Pustular Psoriasis

Pustular psoriasis presents several diagnostic and management challenges to dermatologists. The less common nature of both PPP and GPP can make diagnosis problematic, and treatment decisions are difficult because of limited treatment options. Current management tends to follow treatment options for plaque psoriasis, and guidelines on the management of psoriasis with biologic therapies have recently been published [6, 7]. However, specific guidelines for PPP and GPP are lacking, and there remains an important need for a treatment with high efficacy and rapid onset of action for both forms of pustular psoriasis.

Recent clinical trials of targeted therapies for GPP have shown encouraging results for the management of the debilitating skin diseases within the pustular psoriasis spectrum, and offer the potential to set a new standard in patient care with the possibility of rapid and effective treatment. These emerging drugs for pustular psoriasis offer lower toxicities than existing therapies. The development of new evidence-based guidelines for the management of pustular psoriasis is anticipated for North America and Europe, with the potential to assist clinicians with management decisions, leading to further significant and important improvements in outcomes for patients with both forms of pustular psoriasis.

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 1696 kb)

Pustular psoriasis is a form of psoriasis that is rare in clinical practice and therefore can be difficult to recognize

Treatment is limited by a relative lack of evidence-based therapeutic options

This article summarizes recent advances in understanding of the pathogenesis of pustular psoriasis which have led to new potential treatments, including biologic therapies

The emerging therapies for pustular psoriasis offer the possibility of rapid and effective treatment with lower toxicities than existing therapies